The research on p53 targeted drugs (i.e. drugs that can restore the anti-cancer function of p53 mutants) is highly challenging for two reasons
Although at least 45 teams worldwide are researching drugs to treat p53 mutations, currently only arsenic agents can target p53 mutants and restore their anti-cancer function
Even if arsenic agents have therapeutic effects, they are only effective against structural p53 mutants
PANDA Cancer Research Program: Through basic scientific research, identify mutations in p53 that can be targeted by arsenic agents from over 1000 p53 mutants, forming one of the criteria for arsenic treatment of p53 mutation patients
Population with p53 congenital mutations (LFS)
Multiple types of tumors can occur simultaneously during adolescence, with a lifetime cancer risk of 80-90%, almost 100% for women, and a cancer mortality risk approximately 500 times higher for LFS individuals before the age of 55 compared to normal individuals
Large scale double-blind randomized controlled clinical trials are the only basis for determining the effectiveness of anti-cancer drugs